To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have glioblastoma that has returned or continues to grow despite standard therapy and shows evidence of an activated PI3K pathway.
- At least 4 weeks must have passed since completion of prior therapies (6 weeks since antibody therapy and 12 weeks since radiation therapy) before a patient enters the study.
- Patients may not have had prior treatment with a PI3K inhibitor, mTOR inhibitor, AKT inhibitor, or drugs that target vascular endothelial growth factor (such as bevacizumab, cediranib, aflibercept, vandetanib, or sunitinib).
- Patients must be age 18 or older.
For more information about this study and to inquire about eligibility, please contact the Brain Tumor Hotline at 212-639-6767.